Abbisko’s FGFR4 inhibitor ABSK-012 receives FDA clearance for phase I trials
Nov. 8, 2023
Abbisko Therapeutics Co. Ltd. has received FDA clearance of its IND application for ABSK-012, a highly selective small-molecule inhibitor of fibroblast growth factor receptor 4 (FGFR4), for advanced solid tumors.
